Disease · MONDO_0005109

HIV infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. HIV infectious disease. Diseases, record MONDO_0005109. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005109

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: HIV infectious disease; Open Targets
Open Targets ID: MONDO_0005109; Open Targets
Other names: HIV, HIV - Human immunodeficiency virus infection, HIV INFECT, HIV Infections, HIV infection, HTLV III INFECT, HTLV III Infections, HTLV III LAV INFECT, HTLV III LAV Infections, HTLV WIII INFECTIONS, HTLV WIII LAV INFECTIONS, HTLV-III Infection, HTLV-III-LAV Infection, HUMAN IMMUNO VIRUS DIS, HUMAN IMMUNOdeficiency VIRUS [HIV] INFECTION, Human immunodeficiency virus [HIV] disease, Human immunodeficiency virus caused disease or disorder, Human immunodeficiency virus disease, Human immunodeficiency virus disease (disorder), Human immunodeficiency virus disease or disorder, Human immunodeficiency virus infection, Human immunodeficiency virus infection (disorder), Human immunodeficiency virus infection, NOS, Human immunodeficiency virus infectious disease, Infection, HIV, Infection, HTLV-III, Infection, HTLV-III-LAV, Infections, HIV, Infections, HTLV-III, Infections, HTLV-III-LAV, LYMPHOTROPIC VIRUS TYPE III INFECTIONS HUMAN T, T LYMPHOTROPIC VIRUS TYPE III INFECT HUMAN, T Lymphotropic Virus Type III Infections, Human, Unspecified human immunodeficiency virus [HIV] disease (disorder), [X]Human immunodeficiency virus disease, [X]Human immunodeficiency virus disease (disorder), [X]Unspecified human immunodeficiency virus [HIV] disease, [X]Unspecified human immunodeficiency virus [HIV] disease (disorder), human immunodeficiency virus; Open Targets
Disease Ontology: DOID:526; Disease Ontology
MeSH: D015658; MeSH
NCI Thesaurus: C3108; NCI Thesaurus
Highest stage of its drugs: Approval, for 63 of its 454 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs454

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITONAVIR	CHEMBL163	Small molecule	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD	298	279	279	Drugs and targets
LAMIVUDINE	CHEMBL141	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA, PMDA and TTD	330	258	258	Drugs and targets
ZIDOVUDINE	CHEMBL129	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	276	219	219	Drugs and targets
EMTRICITABINE	CHEMBL885	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	218	174	172	Drugs and targets
EFAVIRENZ	CHEMBL223228	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	187	169	169	Drugs and targets
EMTRICITABINE, (+/-)-	CHEMBL161381	Small molecule	Approval	EMA Human Drugs and TTD	175	154	154	Drugs and targets
LOPINAVIR	CHEMBL729	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	166	150	150	Drugs and targets
DOLUTEGRAVIR	CHEMBL1229211	Small molecule	Approval	EMA Human Drugs and TTD	115	106	106	Drugs and targets
TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Small molecule	Approval	DailyMed	127	105	104	Drugs and targets
RALTEGRAVIR	CHEMBL254316	Small molecule	Approval	EMA Human Drugs and TTD	106	104	104	Drugs and targets

1 to 10 of 454

See all 454 drugs

Targets334

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CCR5	C-C chemokine receptor type 5	7	C-C chemokine receptor type 5 antagonist; C-C chemokine receptor type 5 inhibitor	Approval	https://conductscience.org/library/genes/1234	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	7	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	7	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
PGR	Progesterone receptor	5	Progesterone receptor agonist; Progesterone receptor antagonist	Phase 2	https://conductscience.org/library/genes/5241	Drugs and targets
OPRM1	Mu-type opioid receptor	4	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
SCN10A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets

1 to 10 of 334

See all 334 targets

Trials1,556

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 26 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00004978	An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy	Phase 3	4,150	2011-04-25	HIV Infections	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT04707326	Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study		2,040	2024-12-20	Hiv	DOLUTEGRAVIR, LAMIVUDINE	Its record names the disease	ClinicalTrials.gov
NCT00118898	Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults	Phase 3	1,864	2011-01-10	HIV Infections	ABACAVIR, ATAZANAVIR, EFAVIRENZ, EMTRICITABINE, EMTRICITABINE, (+/-)-, LAMIVUDINE, RITONAVIR, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00811954	Comparative Study of Three NNRTI-Sparing HAART Regimens	Phase 3	1,814	2014-09-05	HIV Infection	ATAZANAVIR, DARUNAVIR, EMTRICITABINE, EMTRICITABINE, (+/-)-, RALTEGRAVIR, RITONAVIR, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00342355	Antiretroviral Therapy for Advanced HIV Disease in South Africa	Phase 4	1,771	2013-04-16	HIV	DIDANOSINE, EFAVIRENZ, LAMIVUDINE, LOPINAVIR, RITONAVIR, STAVUDINE, ZIDOVUDINE	Its record names the disease	ClinicalTrials.gov
NCT00013611	Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)	Phase 3	1,695	2010-12-13	HIV Infection	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT02028676	Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa	Phase 4	1,206	2014-06-06	Human Immunodeficiency Virus	ABACAVIR, LAMIVUDINE, ZIDOVUDINE	Its record names the disease	ClinicalTrials.gov
NCT00561925	VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients	Phase 3	1,068	2012-01-19	HIV Infections	NEVIRAPINE	Its record names the disease	ClinicalTrials.gov
NCT00272779	BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada	Phase 3	1,057	2011-05-09	HIV Infections	ATAZANAVIR, EMTRICITABINE, EMTRICITABINE, (+/-)-, LOPINAVIR, RITONAVIR, TENOFOVIR	Its record names the disease	ClinicalTrials.gov
NCT00255840	Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities	Not applicable	812	2011-06-16	HIV Infections	EFAVIRENZ, LAMIVUDINE, LOPINAVIR, NEVIRAPINE, RITONAVIR, STAVUDINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,556

See all 1,556 trials

Comparisons in its trials473

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
rIL-2 vs No rIL-2: Grade 4 Signs and Symptoms	466 of 2,071	383 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Number of Participants With Changes in Anti-retroviral Treatment (ART)	1,760 of 2,071	1,751 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Number of Participants Who Died From Any Cause	107 of 2,071	116 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Hepatic, Metabolic, and Cardiac Conditions	134 of 2,071	136 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: New or Recurrent Serious HIV Disease Progression Event Including Death	126 of 2,071	130 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: New or Recurrent HIV Disease Progression Event Including Death	159 of 2,071	165 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Participants With a New Disease Progression Event or Death	154 of 2,071	164 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: serious adverse events	466 of 2,071	383 of 2,040	4,111	NCT00004978	Trial comparisons
rIL-2 vs No rIL-2: Pattern of Use of Prophylaxis for Opportunistic Infections	54 of 2,028	53 of 2,005	4,033	NCT00004978	Trial comparisons
Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events, as Defined, or Death.	110 of 849	119 of 846	1,695	NCT00013611	Trial comparisons

1 to 10 of 473

See all 473 comparisons in its trials

Papers from its trials1,001

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41697750	RESULT	1	PubMed
41078080	RESULT	1	PubMed
40136003	RESULT	1	PubMed
38538161	RESULT	1	PubMed
38538160	RESULT	1	PubMed
38536810	RESULT	1	PubMed
37406137	RESULT	1	PubMed
37201510	RESULT	1	PubMed
36729692	RESULT	1	PubMed
36423244	RESULT	1	PubMed

1 to 10 of 1,001

See all 1,001 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005109

GET https://conductscience.org/api/diseases/v1/MONDO_0005109/drugs?page=2

API reference For AI assistants